The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery

Gary Gintant, Bernard Fermini, Norman Stockbridge, David Strauss

Index: 10.1016/j.stem.2017.06.005

Full Text: HTML

Abstract

Nonclinical studies of drug effects with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and efficacy. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons from the cardiac field that also apply to drug studies with other stem cell-based assays.